Table 1.
Baseline information of randomized controlled trials enrolled in the meta-analysis.
| Reference | Number of Patients, N | Classification of Tumor | Treatment arrangement in control group | CRT group | AT regimen in both groups | Treatment interval before surgery | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| CRT group | Control group | Treatment arrangement in CRT group | RT regimen in CRT group | Concurrent CT regimen in CRT group | CRT group | Control group | ||||
| Golcher et al., 2015 (9) | 33 | 33 | resectable PC | surgery+AT | CRT+surgery+AT | 3DCRT, 50.4Gy | 300 mg/m2 Gemcitabine, 30 mg/m2 Cisplatin D1,8,22,29 | Gemcitabine | 11.5 weeks | upfront surgery |
| Joo et al., 2017 (13) | 18 | 19 | BR PC | surgery | CRT+surgery | 3DCRT, 45Gy/18 fraction+9Gy/5 fraction boosting | Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with 400mg/m2 | within 4~6 weeks after operation with Gemcitabine 1000mg/m2 (D1, 8, 15) every 4 weeks, for 4 cycle | 10 weeks | upfront surgery |
| Versteijne et al., 2020 (14) | 119 | 127 | resectable PC 133 BR PC 113 |
surgery+AT | CRT+AT | 36Gy/15 fraction | 1000 mg/m2 Gemcitabine, D1,8,15, 4 weeks | 1000 mg/m2 Gemcitabine D1,8,15, 4 weeks | 14-18 weeks | upfront surgery |
| Jang et al., 2018 (12) | 27 | 23 | BR PC | surgery+AT | CRT+AT | 3DCRT, 45Gy/25 fraction+9Gy/5 fraction boosting | 400 mg/m2 Gemcitabine | 1000 mg/m2 Gemcitabine D1,8,15, every 4 weeks for 4 cycles | Ns | upfront surgery |
| Casadei et al., 2015 (8) | 18 | 20 | resectable PC | surgery+AT | CRT+AT | 45Gy, boost of 9Gy | 50 mg/m2 Gemcitabine | Gemcitabine | 16-18 weeks | upfront surgery |
*BR PC, borderline resectable pancreatic cancer; LA PC, locally advanced pancreatic cancer; AT, adjuvant chemotherapy; IC, induction chemotherapy; CRT, chemoradiotherapy; 3DCRT, 3D conformal radiotherapy. Ns, Not specific.